Document is current
Any future updates will be listed below
-
Authors
Fulgenzi, Claudia A. M.
Dalla Pria, Alessia
Zhao, Yiran
Leone, Alberto Giovanni
Weir, Justin
Puccio, Ignazio
Tuohinto, Krista S.
Ojala, Päivi M.
Bower, Mark
Pinato, David J. https://orcid.org/0000-0002-3529-0103
-
Funding
Funding for this research was provided by:
Sarcoma UK
Chelsea and Westminster Health Charity
- License Information
-
More Information
Article History
Received: 16 December 2025
Revised: 9 May 2026
Accepted: 23 June 2026
First Online: 5 August 2026
Ethics
Competing interests: CAMF received lecture fees from AstraZeneca and Eisai, and consultancy fees from MAIA biotechnology. MB received lecture fees from ViiV and Gilead Sciences, and institutional grants from Gilead Sciences. DJP received consulting fees from Mina Therapeutics, EISAI, Roche, Avamune, DaVolterra, Mursla, H3B, Ipsen, Boston Scientific, Starpharma, Exact Sciences, AstraZeneca, and LIfT Biosciences, and has received honoraria from Roche, BMS, EISAI, and Boston Scientific, and travel support from Roche, BMS, and MSD; received institutional grants from BMS, MSD, and GSK. All other authors declare no competing interests.
Consent for publication: Informed consent for publication of anonymised data was obtained from the study participants.
